Emergency departments (EDs) worldwide are frequently tasked with the management of patients exhibiting acute agitation and delirium. These conditions, which may arise from underlying psychiatric ...

In a randomized, double-blind trial of patients with acute undifferentiated agitation in the emergency department, droperidol was more effective for sedation and was associated with fewer episodes of ...

Good morning, everyone, and thank you for joining us today. I would like to start by welcoming our distinguished participants. We are grateful to each of you for bringing your deep experience in the ...

For both disorders, BXCL501 showed "superiority over placebo" by meeting the primary endpoint of reduction of agitation as measured by the excited component of the Positive and Negative Syndrome Scale ...

A recent review article provides critical insights into the management of acute agitation in reproductive-age females and during pregnancy within the emergency departments (EDs). The study emphasizes ...

Greetings, and welcome to the BioXcel Therapeutics KOL Virtual Roundtable Day. It is now my pleasure to introduce Vimal Mehta, CEO. Thank you. You may begin. I'd like to start by welcoming our ...

NEW HAVEN, Conn., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in ...

Credit: Getty Images Prioritizing nonpharmacologic strategies, enhancing staff training, and distinguishing Delirium Superimposed on Dementia (DSD) are vital to improving outcomes for hospitalized ...

The US Food and Drug Administration (FDA) has approved dexmedetomidine (Igalmi, BioXcel Therapeutics) sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or ...

The approval was based on data from the phase 3 SERENITY I and II studies that evaluated Igalmi for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II, ...